New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
20:25 EDTJNJ, JNJ, JPM, JPM, GS, GS, CMA, CMA, JBHT, JBHT, CBSH, CBSH, WWW, WWW, WAFD, WAFD, WABC, WABCNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.55; JPMorgan (JPM), consensus $1.29; Goldman Sachs (GS), consensus $3.05; Comerica (CMA), consensus 76c; JB Hunt (JBHT), consensus 79c; Commerce Bancshares (CBSH), consensus 68c; Wolverine World Wide (WWW), consensus 27c; Washington Federal (WAFD), consensus 37c; Westamerica Bancorp. (WABC), consensus 58c.
News For JNJ;JPM;GS;CMA;JBHT;CBSH;WWW;WAFD;WABC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 20, 2015
10:09 EDTJPMCiti, JPMorgan, RBS, Barclays, UBS agreed to guilty pleas in forex settlement
Subscribe for More Information
10:08 EDTJPMJPMorgan announces $892M in settlements with DOJ, Fed
JPMorgan Chase announced settlements with the U.S. Department of Justice and the Federal Reserve relating to the bank’s foreign exchange (FX) trading business. Under the DOJ resolution, JPMorgan will plead guilty to a single antitrust violation and pay a fine of $550M. Under the resolution with the Fed, the bank will pay a fine of $342M and has agreed to the entry of a Consent Order. JPMorgan said it has previously reserved for these settlements. These settlements are in addition to agreements announced in November 2014 with the U.K. Financial Conduct Authority, the U.S. Commodity Futures Trading Commission and the U.S. Office of the Comptroller of the Currency relating to the FX trading business. The press release stated, "The conduct underlying the antitrust charge is principally attributable to a single trader (who has since been dismissed) and his coordination with traders at other firms." Jamie Dimon, Chairman and CEO of JPMorgan Chase, said: “The conduct described in the government’s pleadings is a great disappointment to us. We demand and expect better of our people. The lesson here is that the conduct of a small group of employees, or of even a single employee, can reflect badly on all of us, and have significant ramifications for the entire firm. That’s why we’ve redoubled our efforts to fortify our controls and enhance our historically strong culture."
10:00 EDTCMAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Achillion (ACHN) downgraded on valuation at JMP Securities... Ashland (ASH) downgraded to Equal-Weight from Overweight at First Analysis... Bank of Nova Scotia (BNS) downgraded to Underperform from Neutral at BofA/Merrill... Braskem (BAK) downgraded to Neutral from Overweight at JPMorgan... Comerica (CMA) downgraded to Underperform at Baird... Crestwood Midstream (CMLP) downgraded to Neutral from Buy at Ladenburg... Fifth Third (FITB) downgraded to Neutral from Outperform at Baird... Keurig Green Mountain (GMCR) downgraded to Hold from Buy at Argus... Keysight Technologies (KEYS) downgraded to Neutral from Outperform at Baird... Leju (LEJU) downgraded to Underperform from Buy at CLSA... Marrone Bio (MBII) downgraded to Hold from Buy at Jefferies... Southwest (LUV) downgraded to Neutral from Buy at Buckingham... SunTrust (STI) downgraded to Market Perform from Outperform at Keefe Bruyette... Western Alliance (WAL) downgraded to Market Perform from Outperform at Keefe Bruyette.
09:07 EDTJNJJohnson & Johnson says exploring eight new indications for Imbruvica
Imbruvica is jointly developed and commercialized by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ) subsidiary Janssen Biotech. AbbVie (ABBV) is in the process of acquiring Pharmacyclics.
08:49 EDTJNJJohnson & Johnson: Priorities for free cash flow include dividends, repurchases
Subscribe for More Information
08:30 EDTJNJAchillion price target lowered to $16 from $25 at Leerink
Leerink says Achillion's deal with Johnson & Johnson (JNJ) increases the probability that it will be a competitive commercial-stage player in hepatitis C. The firm believes the collaboration limits share downside as well as upside by making the "home-run scenario of great combo data leading to an acquisition less likely." It lowered its price target for Achillion shares to $16 and keeps an Outperform rating on the name.
08:21 EDTGS, JPMATM data theft soars to highest rate in two decades, WSJ says
Subscribe for More Information
08:15 EDTJNJJohnson & Johnson CEO Alex Gorsky says won't pursue pure-play strategy
Subscribe for More Information
08:02 EDTJNJJohnson & Johnson to hold a meeting
Subscribe for More Information
07:51 EDTJNJAchillion shares remain undervalued after HCV pact with J&J, says Cowen
Subscribe for More Information
07:33 EDTJNJJ&J to file more than 10 new '$1B potenital' products by 2019
Subscribe for More Information
07:30 EDTJNJAchillion downgraded on valuation at JMP Securities
Subscribe for More Information
06:39 EDTCMAComerica downgraded to Underperform at Baird
As previously reported, Baird downgraded Comerica to Underperform from Neutral and increased its price target to $44 from $40. The firm downgraded shares due to below consensus 2016 earnings estimates, and lower NIM and loan growth forecasts.
06:17 EDTJNJAchillion downgraded to Neutral from Buy at UBS
Subscribe for More Information
06:16 EDTCMAComerica downgraded to Underperform from Neutral at Baird
Subscribe for More Information
May 19, 2015
16:10 EDTJNJAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation – JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
15:42 EDTJPMBanks' settlement over forex rigging to be announced tomorrow, CNBC says
Several banks are said to plan to plead guilty and pay "billions" in fines in a settlement over their roles in foreign exchange manipulation that is expected to be announced Wednesday, according to CNBC's Kate Kelly. Prior media reports have listed Barclays (BCS), Royal Bank of Scotland (RBS), UBS (UBS), JPMorgan (JPM) and Citigroup (C) as having been in talks with U.K. and U.S. authorities for their roles in foreign currency rigging.
09:37 EDTJPMActive equity options trading on open
Subscribe for More Information
May 18, 2015
09:46 EDTJPMMPLX enters common unit sales agreement for up to $500M
Subscribe for More Information
07:12 EDTJPMBarclays expected to face over GBP250M in fines for rigging, Telegraph says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use